

You have already added 0 works in your ORCID record related to the merged Research product.
You have already added 0 works in your ORCID record related to the merged Research product.
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=undefined&type=result"></script>');
-->
</script>
You have already added 0 works in your ORCID record related to the merged Research product.
You have already added 0 works in your ORCID record related to the merged Research product.
Antibody Characterization Report for Optineurin
Antibody Characterization Report for Optineurin
Head to head comparison of available commercial antibodies against Optineurin by immunoblot (Western blot), immunoprecipitation and immunofluorescence. This work is part of the ALS-Reproducible Antibody Platform (ALS-RAP). ALS-RAP was created as a public-private partnership by three leading ALS charities - the ALS Association (USA), the Motor Neurone Disease Association (UK), and the ALS Society of Canada.
FIP-2, Huntingtin yeast partner L, TFIIIA-IntP, Antibody validation, NEMO-related protein, Antibody characterization, Amyotrophic lateral sclerosis, ALS-RAP, Huntingtin-interacting protein 7, Transcription factor IIIA-interacting protein, OPTN, HIP-7, Optic neuropathy-inducing protein, E3-14.7K-interacting protein, Optineurin, Huntingtin-interacting protein L
FIP-2, Huntingtin yeast partner L, TFIIIA-IntP, Antibody validation, NEMO-related protein, Antibody characterization, Amyotrophic lateral sclerosis, ALS-RAP, Huntingtin-interacting protein 7, Transcription factor IIIA-interacting protein, OPTN, HIP-7, Optic neuropathy-inducing protein, E3-14.7K-interacting protein, Optineurin, Huntingtin-interacting protein L
16 Research products, page 1 of 2
- 2021IsAmongTopNSimilarDocuments
- 2022IsAmongTopNSimilarDocuments
- 2023IsAmongTopNSimilarDocuments
- 2022IsAmongTopNSimilarDocuments
- 2023IsAmongTopNSimilarDocuments
- 2022IsAmongTopNSimilarDocuments
- 2022IsAmongTopNSimilarDocuments
- 2022IsAmongTopNSimilarDocuments
- 2021IsAmongTopNSimilarDocuments
- 2022IsAmongTopNSimilarDocuments
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average visibility views 246 download downloads 168 citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average Powered byBIP!
- 246views168downloads



Head to head comparison of available commercial antibodies against Optineurin by immunoblot (Western blot), immunoprecipitation and immunofluorescence. This work is part of the ALS-Reproducible Antibody Platform (ALS-RAP). ALS-RAP was created as a public-private partnership by three leading ALS charities - the ALS Association (USA), the Motor Neurone Disease Association (UK), and the ALS Society of Canada.